Entrada Therapeutics shares plunge after Duchenne trial shows modest dystrophin increase

Entrada Therapeutics reported early data from a Phase 1/2 study of its RNA‑based therapy ENTR‑601‑44 for Duchenne muscular dystrophy, noting favorable safety and tolerability.

The trial showed a dystrophin increase of only 2.36%, well below analyst expectations of 10% or more, prompting disappointment among investors.

Following the announcement, Entrada's stock dropped roughly 55%, reflecting the market's reaction to the underwhelming efficacy signal.

Analysts cautioned that the modest result may hinder the company's ability to compete with more advanced Duchenne candidates currently in development.